64 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
needs and the board of directors’ assessment of its leadership from time to time. We currently separate the roles of chief executive officer … assessment and risk management policies;
reviewing with management our cybersecurity and other information technology risks, controls and procedures
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
on these data and our assessment of ongoing areas of high unmet need, we advanced tamibarotene in combination with azacitidine into a registration … , statute or constitutional provision or by the enforcement of any assessment or by any legal or equitable proceeding or otherwise. Each holder
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
6 Dec 23
Regulation FD Disclosure
7:05am
patients non-evaluable 2 recently enrolled and have not reached the initial response assessment as of the November 13, 2023 data cut-off 1 patient … discontinued during cycle 1 (prior to starting tamibarotene) without a response assessment 1 Ven/Aza patient non-evaluable Discontinued study treatment
424B3
txsj3d py
8 Aug 22
Prospectus supplement
5:47pm
S-4
j76uz299 h4m24ew
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
425
eaw0 u4tu2bnm9yjr7e
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-2.1
lzw7z0
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am